Medication info

Glian Duo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin Amorphous›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
International Pharmaceuticals Co., Ltd.
Appearance
Biconvex oval film-coated tablet with light brownish-purple color
Packaging
30 tablets/box [(6 tablets/PTP × 5)]
Approval status
Active

MFDS item code 202501692 · Approved 2025.07.08

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients in Whom the Medicine Must Not Be Used, item 2)). Elderly patients Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.

Ingredients

Manufacturer
International Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Poor blood sugar control in adult type 2 diabetes patients
  • cardiovascular diseases
View approved original text

This medication is used to improve blood sugar control as an adjunct to diet and exercise in adults with type 2 diabetes through the combination of empagliflozin and metformin. It is especially necessary for proper management in patients with cardiovascular diseases who do not achieve adequate blood sugar control. Therefore, this medication aids in effective blood sugar management while considering cardiovascular risk.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients in Whom the Medicine Must Not Be Used, item 2)). Elderly patients Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.

Precautions

This medication is used for the treatment of diabetes and contains empagliflozin and metformin hydrochloride as the main ingredients. Caution should be exercised for severe lactic acidosis, a rare side effect associated with this medication. Lactic acidosis can be life-threatening, with symptoms including malaise, muscle pain, difficulty breathing, and abdominal pain. When taken with other diabetes medications, hypoglycemia may occur, so blood sugar levels should be closely monitored. This medication should not be used in patients with moderate to severe impaired kidney function or acute kidney problems, severe infections, or heart failure. This medication should be temporarily discontinued before and after examinations using radiocontrast agents containing iodine, and should be restarted only after kidney function has been confirmed to be normal. Women who are pregnant or breastfeeding should avoid taking this medication, and excessive alcohol consumption should also be avoided. This medication may cause side effects such as genital infections, urinary tract infections, and increased urination; consultations with a doctor should be made if these symptoms occur. Elderly patients or those with impaired kidney function should undergo regular kidney function tests and may require dose adjustments if necessary. Furthermore, while taking this medication, vitamin B12 levels may decrease; therefore, regular blood tests are recommended for those on long-term treatment. Patients scheduled for surgery should discontinue this medication 48 hours prior to the procedure and can resume it only after kidney function has returned to normal postoperatively. This medication can cause symptoms of hypoglycemia, so caution is necessary if meals are skipped or irregular. In cases of overdose, especially with metformin, the risk of lactic acidosis is higher, and immediate medical attention is required.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 212 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbances
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvovaginitis
  • vulvar vaginitis
  • balanitis
  • perineal necrosis
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disorders
  • oral discomfort
  • salivary gland pain
  • headache
  • sensory loss
  • position-induced dizziness
  • dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • colorectal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • hematuria
  • hyperactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • wet cough
  • allergic rhinitis
  • sputum retention
  • cough
  • skin laceration
  • bruise
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • gastric cancer
  • leiomyoma
  • pancreatic adenocarcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • anxiety
  • depression
  • sleep disorders
  • dysmenorrhea
  • position-induced dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • chest discomfort
  • vulvar pruritus
  • genital pruritus
  • hypoglycemia
  • decreased appetite
  • obesity
  • acanthosis nigricans
  • hyperlipidemia
  • back pain
  • diabetic neuropathy
  • facial paralysis
  • sleepiness
  • CNS-origin dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture, and it should be kept at a temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Biconvex oval film-coated tablet with light brownish-purple color

Package unit

30 tablets/box [(6 tablets/PTP × 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.